ClinicalTrials.gg
CompletedNCT02187991Updated Oct 9, 2024Results posted

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

A Phase 2 interventional study of Paclitaxel and Alisertib in Breast Cancer, Breast Carcinoma and Breast Tumors, sponsored by US Oncology Research. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Breast Neoplasms by Sarah Cannon Research Institute — none open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Sarah Cannon Research Institute.

Enrollment
3rd of 10
169 · median 120
Started
2015
the only one that year
Phase 2
8 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Breast Neoplasms by Sarah Cannon Research Institute, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2015, is one of 8 in phase 2, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 11 studies in Breast Neoplasms by Sarah Cannon Research Institute is open now. The open studies under Breast Neoplasms, anywhere →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Breast Neoplasms by Sarah Cannon Research Institute as a file.
02

Study summary

The goal of this clinical research study is to learn if the study drug, alisertib (MLN8237), in combination with chemotherapy (paclitaxel), can shrink or slow tumor growth in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative or HR-negative, HER2-negative (triple negative) locally recurrent or metastatic breast cancer (MBC). The safety of alisertib in combination with paclitaxel will also be studied. The physical state of the patient, symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if alisertib plus paclitaxel is safe and effective in patients with this type of breast cancer.

Alisertib belongs to a group of drugs called Aurora kinase inhibitors. Alisertib blocks the activity of Aurora A kinase, a protein that is involved in tumor cell multiplication and survival. Aurora A kinase is expressed at higher than normal levels in many types of cancer, including breast cancer, and preclinical studies suggest that blocking the activity of this protein can lead to the death of cancer cells.

Paclitaxel is a chemotherapy drug commonly used to treat many different kinds of cancer, including metastatic breast cancer. The reason to combine alisertib and paclitaxel is that in cancer therapy, combinations of drugs are often more effective as a treatment than either of the same drugs used alone.

Read the detailed description

The rationale behind assessing the effectiveness of the addition of alisertib to weekly paclitaxel therapy in patients with Triple Negative Breast Cancer and highly proliferative estrogen receptor-positive (ER+) and HER2- breast cancer is based on the unmet clinical need for effective strategies to prevent or delay resistance to taxane therapy in the metastatic setting. Synergistic or additive effects have been observed in breast cancer xenograft models which involved alisertib added to either paclitaxel or docetaxel. Alisertib inhibited the Pgp-mediated efflux of paclitaxel in a cell culture model. In addition, Aurora Kinase A is frequently overexpressed in Triple Negative Breast Cancer (TNBC), and expression levels have been shown to be prognostic in both of these breast cancer subtypes. The combination of alisertib with paclitaxel has also been investigated in a Phase 1 study in patients with locally advanced or metastatic ovarian and breast cancers, with preliminary evidence of activity in both tumor types including 6 partial response (PR)s and 3 stable disease (SD) in 11 patients with metastatic breast cancer.

03

Conditions studied

  • Breast Cancer
  • Breast Carcinoma
  • Breast Tumors
  • Malignant Neoplasm of Breast

Keywords

  • metastatic breast cancer
  • Human Epidermal Growth Factor Receptor 2-negative (HER2-) breast cancer
  • Estrogen Receptor-positive (ER+) breast cancer
  • Triple Negative breast cancer
  • alisertib
  • paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care, and signed Health Insurance Portability and Accountability Act (HIPAA) form.
  • Female subject (≥18 years old), who is either:

    • for at least one year before the screening visit, or
    • surgically sterilized, or
    • willing to use an acceptable method of (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide) for the duration of the study.
  • or locally recurrent breast cancer with histologic confirmation (on either primary or metastatic tumor) of one of the following:

    • ER+, - invasive breast cancer (any progesterone receptor [PgR] status)
    • Poorly differentiated and/or Grade 3 invasive TNBC, defined as:
    • HER2 negative status (based on most recently analyzed ) is defined as immunohistochemistry (IHC) status of 0, 1+ or 2+ (if IHC 2+, a negative FISH test is required, i.e., HER2 fluorescence in situ hybridization (FISH) ratio \< 2.0 with an average HER2 copy number \<4.0 signals/cell); ER-negative and PR-negative status is defined as ER and PgR \<1% nuclei positive by IHC
  • by modified (RECIST) (v1.1) or non-measurable lytic, bone-only disease (mixed blastic/lytic bone disease is allowed); if patient has bone-predominant disease with no measurable disease, there must be a lytic component to the bone metastases that is visible on plain X-ray or CT scan that can be serially followed
  • (ANC) > 1500/mm³, > 100,000/mm³, > 9 g/dL. Values must be obtained without need for myeloid growth factor or platelet transfusion support within 14 days, however, erythrocyte growth factor is allowed as per published American Society of Clinical Oncology (ASCO) guidelines (available at: http://www.asco.org/quality-guidelines/asco-ash-clinical-practice-guideline-update-use-epoetin-and-darbepoetin-adult).
  • Total ≤ 1.5 x (ULN), serum glutamic-oxaloacetic transaminase () (AST) and serum glutamic-pyruvic transaminase (SGPT) (ALT) \< 2.5 x ULN. AST and/or ALT may be up to 5 x ULN if patient has known liver metastases
  • Adequate renal function as defined by: Calculated must be ≥ 30 mL/minute (see Cockcroft-Gault formula in Appendix 5)
  • (ECOG) performance status 0 or 1 (refer to Appendix 4)

Exclusion criteria

Exclusion Criteria:

  • Previous radiation therapy covering the whole pelvis
  • Suspected , untreated brain metastases or current clinical or radiologic progression of known brain metastases or requirement for therapy for brain metastases

    • Patients with treated brain metastases are eligible if they have been stable and off steroids for ≥ 3 weeks
  • Prior allogeneic bone marrow or organ transplantation
  • Known GI disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib. Examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease
  • Known history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe ; requirement for supplemental oxygen.
  • Requirement for administration of proton pump inhibitor, or for constant administration of H2 antagonist, or pancreatic enzymes. Intermittent uses of antacids or H2 antagonists are allowed as described in Section 3.4.
  • Systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection.
  • Myocardial infarction within 6 months prior to enrollment or has (NYHA) Class III or IV heart failure (see Appendix 3), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality at Screening has to be documented by the investigator as not medically relevant.
  • Female subject who is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening, within 72 hours prior to first dose of study drug(s). Pregnancy testing is not required for or surgically sterilized women.
  • Patient has received an agent within 30 days before enrollment
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Other severe acute or chronic medical and/or psychiatric condition(s), including but not limited to uncontrolled diabetes, malabsorption, resection of the pancreas or upper small bowel, requirement for pancreatic enzymes, any condition that would modify small bowel absorption of oral medications, or laboratory abnormalities that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient not eligible for enrollment for this study.
  • Diagnosed or treated for another within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, or an in situ malignancy, or a stage I cancer with a 5-year Disease Free Survival (DFS) of ≥ 90% (survival rates by stage are available for most cancers on the American Cancer Society website).
  • Treatment with enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of alisertib and during the study.
  • Known history of (HIV) infection, , or . Testing is not required in the absence of clinical findings or suspicion. For guidance in defining active infection for hepatitis B, please refer to the World Health Organization (WHO) guidelines, Global Alert and Response (GAR), Hepatitis B. http://who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index4.html)
  • Prior administration of an Aurora A kinase-targeted agent, including alisertib
  • Need for ongoing therapeutic steroid therapy. Intermittent steroid use for the control of nausea and vomiting is allowed. Premedication with dexamethasone prior to paclitaxel administration is allowed. Topical steroid use is permitted. Inhaled steroids are permitted. Replacement doses of hydrocortisone up to 15 mg/day are allowed.
  • Inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib.
  • Administration of myeloid growth factors or transfusion within 14 days prior to the first dose of study treatment.
  • More than 1 previous chemotherapy regimen for disease

    • No limit on previous endocrine therapy
    • Previous mammalian target of rapamycin (mTOR) therapy, e.g., everolimus, is allowed
    • Prior taxane therapy is allowed, provided the disease-free interval from the end of (neo)adjuvant chemotherapy to the development of metastatic disease was ≥ 1 year
    • No prior taxane for metastatic disease
  • Peripheral neuropathy > grade 1
  • Known severe to paclitaxel
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
169 participants (actual)

Study arms

  • Active comparator
    ER+/HER2- Paclitaxel Alone

    Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle

    Drug: Paclitaxel

  • Experimental
    ER+/HER2- Paclitaxel plus Alisertib

    Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg twice a day (BID) on days 1-3, 8-10, and 15-17 of a 28-day cycle

    Drug: Paclitaxel · Drug: Alisertib

  • Active comparator
    Triple Negative Paclitaxel Alone

    Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle

    Drug: Paclitaxel

  • Experimental
    Triple Negative Paclitaxel plus Alisertib

    Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle

    Drug: Paclitaxel · Drug: Alisertib

Interventions

  • either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)

    Also known as: Taxol, Abraxane

  • 40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Time to Disease Progression - Tumor Response Based on RECIST 1.1 Criteria

    Measurement of tumors (sum of longest diameters) every 8 weeks for CT/MRI and photographs, and every 12 weeks for bone scan, if applicable. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions (plus an absolute increase of at least 5 mm), or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 3 years from date of patient registration

Secondary outcomes

  1. Overall Survival

    Time from randomization to death from any cause

    Time frame: up to 4 years from date of patient registration

07

Results

Posted Oct 9, 2024
Limitations and caveats
This study has some limitations. First, poor accrual to the TN MBC cohort, likely owing to paclitaxel alone control arm, precludes reliable interpretation of the limited data obtained in this trial. In addition, ER-positive, ERBB2-negative MBC is a heterogeneous disease, and this study does not provide insight into how to identify patients who may benefit from adding alisertib to paclitaxel, as well as those who may not benefit.

Participant flow

Between February 2015 and February 2018, a total of 169\* women were enrolled in the trial and were randomly assigned to paclitaxel alone (85 patients), or paclitaxel plus alisertib (84 patients) cohorts. \*174 women were consented and included in baseline demographics. However, 5 of these did not start study treatment due to ineligibility, participant withdrawal, and/or investigator decision, so only 169 participants were included in Participant Flow and AE/SAE analysis.

Participant flow — Overall Study
MilestoneER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus Alisertib
Started70661518
Completed3638810
Not completed342878
Withdrew: Adverse event131432
Withdrew: Withdrawal by subject9632
Withdrew: Physician decision4402
Withdrew: Other, unrelated complication7112
Withdrew: Death1300

Outcome measures

PrimaryTime to Disease Progression - Tumor Response Based on RECIST 1.1 Criteria

Measurement of tumors (sum of longest diameters) every 8 weeks for CT/MRI and photographs, and every 12 weeks for bone scan, if applicable. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions (plus an absolute increase of at least 5 mm), or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 3 years from date of patient registration
Reported as:
Median · months
Time to Disease Progression - Tumor Response Based on RECIST 1.1 Criteria
monthsER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus Alisertib
Time to Disease Progression - Tumor Response Based on RECIST 1.1 Criteria7.1 (3.8 to 10.6)10.2 (3.8 to 15.7)5.7 (2.9 to 8.2)9.6 (6.1 to 22.6)
SecondaryOverall Survival

Time from randomization to death from any cause

Time frame:
up to 4 years from date of patient registration
Reported as:
Median · months
Overall Survival
monthsER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus Alisertib
Overall Survival25.1 (16.0 to 30.5)26.3 (18.7 to 37.2)12.7 (6.8 to 23.5)16.0 (9.6 to 34.0)

Adverse events

Collected over until 30 days after last dose of patient's study treatment, for up to 2 years from date of registration (enrollment into study). However, mortality data was collected for up to 4 years from date of registration.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ER+/HER2- Paclitaxel Alone43/70 (61.4%)2/70 (2.9%)69/70 (98.6%)
ER+/HER2- Paclitaxel Plus Alisertib39/69 (56.5%)13/66 (19.7%)65/66 (98.5%)
Triple Negative Paclitaxel Alone14/16 (87.5%)0/15 (0%)15/15 (100%)
Triple Negative Paclitaxel Plus Alisertib13/19 (68.4%)6/18 (33.3%)18/18 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus Alisertib
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/701/660/152/18
SEPSISInfections and infestations0/701/660/152/18
DIARRHEAGastrointestinal disorders0/703/660/151/18
INFECTION FUNGALInfections and infestations0/700/660/151/18
NEUTROPENIABlood and lymphatic system disorders1/702/660/150/18
NAUSEAGastrointestinal disorders0/701/660/150/18
CHEST PAINGeneral disorders0/701/660/150/18
NEUROPATHY PERIPHERALNervous system disorders0/701/660/150/18
EMBOLISM PULMONARYRespiratory, thoracic and mediastinal disorders0/701/660/150/18
INFECTION RESPIRATORYRespiratory, thoracic and mediastinal disorders0/701/660/150/18
Most frequent other events
Showing 10 of 35
Most frequent other events
EventER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus Alisertib
NEUTROPENIABlood and lymphatic system disorders13/7043/665/1514/18
DIARRHEAGastrointestinal disorders7/7039/664/159/18
FATIGUEGeneral disorders27/7033/667/159/18
ALOPECIASkin and subcutaneous tissue disorders31/7031/664/154/18
NAUSEAGastrointestinal disorders18/7028/666/157/18
ANEMIABlood and lymphatic system disorders6/7016/665/156/18
CONSTIPATIONGastrointestinal disorders11/707/663/156/18
MUCOSITIS ORALGastrointestinal disorders3/7019/661/154/18
HEADACHENervous system disorders3/706/662/155/18
NEUROPATHY PERIPHERALNervous system disorders12/704/664/151/18

Baseline characteristics

174 participants were consented and included in baseline analysis. However, 5 of these did not start study treatment due to ineligibility, participant withdrawal, and/or investigator decision, so only 169 participants were included in Participant Flow and Adverse Event/Serious Adverse Event (AE/SAE) Analysis.

Age, Categorical
Age, Categorical(Participants)ER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus AlisertibTotal
<=18 years00000
Between 18 and 65 years25314666
>=65 years45381213108
Age, Continuous
Age, Continuous(years)ER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus AlisertibTotal
Median63.2 (26.9 to 84.2)62.5 (33.1 to 83.4)65.2 (53.1 to 81.3)63.2 (38.8 to 75.0)63.2 (26.9 to 84.2)
Sex: Female, Male
Sex: Female, Male(Participants)ER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus AlisertibTotal
Female70691619174
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus AlisertibTotal
Asian11103
Black676423
Caucasian5554913131
Hispanic660214
Other21003
Region of Enrollment
Region of Enrollment(Participants)ER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus AlisertibTotal
United States70691619174
Positive Nodes
Positive Nodes(Participants)ER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus AlisertibTotal
036337985
1-320203447
4 or more9135532
Missing531110
Prior Chemotherapy for Metastatic Disease
Prior Chemotherapy for Metastatic Disease(Participants)ER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus AlisertibTotal
No prior chemotherapy48481113120
1 prior chemotherapy22215654
Current Histology
Current Histology(Participants)ER+/HER2- Paclitaxel AloneER+/HER2- Paclitaxel Plus AlisertibTriple Negative Paclitaxel AloneTriple Negative Paclitaxel Plus AlisertibTotal
Ductal47451116119
Lobular1091020
Mixed DL22004
Other11134230
Missing00011
08

Study locations

1 site
  • 22 Sites
    Including Dallas And Austin, Texas, United States
09

References and documents

Publications

  • O'Shaughnessy J, McIntyre K, Wilks S, Ma L, Block M, Andorsky D, Danso M, Locke T, Scales A, Wang Y. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2021 Apr 1;4(4):e214103. doi: 10.1001/jamanetworkopen.2021.4103. PubMed 33877311 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Apr 2024, 109 months.

Results were first posted in Oct 2024, 5 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 109 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2014
First posted
Jul 11, 2014
StartActual
Feb 12, 2015
Primary completionActual
Apr 11, 2024
CompletionActual
Aug 1, 2024
Results first posted
Oct 9, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02187991
Responsible party
Sponsor
First posted
Jul 11, 2014
Start date
Feb 12, 2015
Primary completion
Apr 11, 2024
Completion
Aug 1, 2024
Results posted
Oct 9, 2024
Last update
Oct 9, 2024

Study contacts

Joyce A. O'Shaughnessy, MD
principal investigator · US Oncology Research, McKesson Specialty Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion